Talking Tumors: Leveraging Immunotherapy in Nonsquamous NSCLC
We recently traveled to Little Rock, Arkansas, for a State of the Science Summit™ on Non–Small Cell Lung Cancer. In advance of the meeting, we conducted a Twitter poll regarding the use of single-agent immunotherapy versus combination chemotherapy and immunotherapy in a patient with nonsquamous non–small cell lung cancer. During the meeting, we also asked our attendees to answer the poll to gauge their thoughts on these treatment interventions and see how the results compare.
In keeping up with the constant and sometimes controversial landscape of non–small cell lung cancer, we sat down with Stephen V. Liu, MD, of Medstar Georgetown University Medical Center, and Konstantinos Arnaoutakis, MD, of Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, to further discuss the results of the poll and shed light on the data that support each intended treatment choice.